Report Overview

Indian Autoimmune Hemolytic Amemia (AIHA) Drugs market size stood at around USD XX Billion in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.

Autoimmune hemolytic anemia (AIHA) is also called immune hemolytic anemia. It is an immune and rare red blood cell disorder. Autoimmune hemolytic anemia occurs when the immune system makes antibodies that attack red blood cells in the body. This decreases the number of red blood cells, resulting to hemolytic anemia. Common symptoms of autoimmune hemolytic anemia include breathing difficulties, dark urine and/or splenomegaly, jaundice, and weakness & fatigue with tachycardia. Autoimmune hemolytic anemia can be idiopathic or can result from medication or an underlying disease. Major types of autoimmune hemolytic anemia include cold antibody hemolytic anemia and warm antibody hemolytic anemia. Treatment for autoimmune hemolytic anemia can include splenectomy, corticosteroids such as prednisone, immunosuppressive drugs, and/or blood transfusions.



Market Drivers

The Indian autoimmune hemolytic anemia therapeutics market is primarily driven by increase in the use of drugs such as corticosteroids for patients with autoimmune hemolytic anemia. Corticosteroids are highly preferred to minimize complications such as osteoporosis, diabetes, obesity, and uncontrolled hypertension. Limited number of drugs are available for autoimmune hemolytic anemia treatment. This has encouraged biotechnology researchers and pharmaceutical companies to invest in research & development to develop novel therapies such as parsaclisib and fostamatinib. Additionally, rise in demand for the development of combination therapies and anemia therapeutics in patient assistance programs is expected to drive the Indian autoimmune hemolytic anemia therapeutics market.